N ucleic acid detection technology is revolutionizing microbiological diagnostic testing. With the exception of infectious prion proteins, all pathogenic microbes contain DNA and / or RNA and are thus targets for nucleic acid-based testing. Some clinical microbiology laboratories are largely shifting to nucleic acid testing, which is particularly useful for detecting slow-growing or unculturable organisms such as viruses, mycobacteria, and fastidious bacterial pathogens. However, significant challenges remain before this technology can be applied universally in clinical laboratories.
The core of nucleic acid tests in clinical microbiology laboratories is the polymerase chain reaction (PCR). Although PCR can rapidly provide clinically useful information regarding the presence of pathogens, its incredible specificity hinders its utility for broadspectrum detection. The adage, "you only find what you're looking for" applies to PCR as well as most nucleic acid-based tests. Moreover, detecting an infectious agent yields only half the picture. Another part of the clinically useful information is based on susceptibility profiles. Genotyping through nucleic acid testing reliably predicts single-gene instances of drug resistance in both viruses and bacteria. More complicated resistance mechanisms involving multiple genes and interacting mutations require more comprehensive testing methods than PCR. Another reason why nucleic-acid detection methods other than PCR are needed is that clinical syndromes such as pneumonia, gastroenteritis, sepsis, and eucephalitis are not specific for any one pathogen or category of pathogens. The "one test-one pathogen" paradigm can prove costly, inefficient, and time-consuming. In addition, diagnostic microbiology tests routinely fail to detect novel or unusual pathogens. Thus, in the clinical microbiology laboratory, we do not identify the etiology for about 25% of cases of acute respiratory illness, 50% of diarrheal diseases, and more than 70% of encephalitis, despite extensive conventional testing.
The emergence of novel pathogens further confounds diagnostic efforts in clinical microbiology. During the past century,
Summary
• High-density microarrays such as the Virochip pan-viral microarray and deep sequencing can test for thousands of potential pathogens simultaneously.
• Identifying a novel or unusual infectious agent from clinical samples does not prove that it causes a disease, and further investigation is required to show that it is a pathogen • Interpreting data, setting quality control standards, and meeting regulatory requirements are among the challenges facing those who are adapting these technologies for diagnostic use.
• These technologies are enabling microbiologists to conduct broad-based surveillance for novel infectious agents that elude conventional testing and in the near future are likely to radically transform the way clinical microbiology laboratories approach infectious disease diagnosis. In the face of those needs, microbiologists are adapting nucleic acid technologies to detect pathogens on a broad-spectrum basis, relying in part on high-density microarrays and deep sequencing. Rooted in metagenomics, the analysis of complex mixtures of nucleic acids, these technologies are being used for comprehensive surveillance and to identify novel pathogens. Although these approaches provide great opportunities, they also come with considerable challenges to be met amidst an increasingly complex and stringent regulatory landscape.
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Microarray Technology in Clinical Diagnostics
DNA microarrays use probes to detect sequences that are complementary to those probes, which are immobilized on solid surfaces or attached to small beads and can interrogate millions of sequences in a single assay. In microbiology, such arrays are used in several ways, including to speciate bacteria and fungi, to investigate microbial diversity in complex environmental samples, to analyze transcripts, and to identify pathogens.
Various microarrays are being used for clinical microbiology diagnostics, and the panels of infectious agents that they can detect are continually expanding. For example, Luminex markets a panel of probes for detecting 12 viral agents of upper respiratory tract infection (the Luminex RVP TM Assay); this microbead-based panel is licensed by the Food and Drug Administration (FDA), while its larger panel is already used in Europe. Meanwhile, Autogenomics has several research-use-only (RUO) probe panels for identifying or typing respiratory viruses, human papillomavirus (HPV), mycobacteria, and agents that cause vaginitis. A number of companies, including Akonni, TessArae, and Veredus, produce RUO assays for detection of influenza virus. Typically, these microarray-based technologies are limited to approximately 100 probes, detecting only the most common pathogens or strains but not meant for comprehensive analysis.
Our group at University of California, San Francisco (UCSF) is developing microarrays for two main purposes, conducting broad-spectrum surveillance and discovering viral pathogens. The Virochip, which we use, and GreeneChip, a similar platform designed by Ian Lipkin and his colleagues at Columbia University, New York, N.Y., are microarrays containing thousands of probes to target all viral families known to infect humans. The probes on these arrays contain elongated, 70-mer oligonucleotides to increase their sensitivity for diverse viral strains. Both platforms employ a primer-independent random amplification technique to enable unbiased detection. Initially, probes chosen for the Virochip were based on nucleic acid sequences from the most conserved regions of viral families. Probes were later added to cover other nodes in the viral taxonomy at the family, genus, and species levels. Moreover, the Virochip probes are updated regularly, with the v5.0 version from October 2009 containing about 36,000 probes. Its sensitivity is superior to direct fluorescent antibody tests and comparable to PCR for detecting respiratory genomes at levels as low as 100 genome copies based on testing for rhinoviruses.
We used the Virochip to diagnose the cause of a severe respiratory infection in an immunocompetent, 28-year-old woman, who was admitted to the hospital in 2005 with a 10-day history of fever, cough, and night sweats. Her chest radiograph revealed nonspecific bilateral infiltrates, and a CT scan had a tree-in-bud appearance, suggesting bronchiolitis ( Fig. 1A and B) . After being treated with broad-spectrum antibiotics, she developed acute respiratory failure requiring mechanical ventilation. Conventional testing for over 30 infectious agents proved negative, and an open-lung biopsy was unrevealing (Fig. 1C) . However, based on our Virochip analysis (Fig. 1E) , we determined that she was infected with the human parainfluenza 4 virus (HPIV-4). This finding was unexpected because HPIV-4 is primarily associated with mild upper respiratory infections in children and adults. The diagnosis was confirmed by direct RT-PCR amplification and sequencing, as well as serological analysis (Fig. 1D) .
Clinical Applications of Pathogen Discovery
The Virochip is actively being used to identify other viral agents associated with disease. In 2006, for example, we reported its use to identify the XMRV retrovirus in prostate cancer patients. Other research groups have subse- quently detected this virus in association with chronic fatigue syndrome. The Virochip also helped to identify the SARS coronavirus, a new clade of rhinoviruses, a divergent human metapneumovirus infection in a patient with critical respiratory illness, avian bornavirus (the viral agent of an HIV-like illness in parrots), and a novel human cardiovirus.
The clinical utility of this approach comes from detecting novel or previously uncharacterized agents that truly cause disease. For example, our unanticipated finding of severe HPIV-4 infection in a healthy young adult expanded the documented clinical spectrum of this pathogen, supporting specific testing for HPIV-4 in individuals with severe respiratory illness of unknown cause. Subsequent research confirmed that HPIV-4 may indeed be an underappreciated cause of respiratory infections in nursing home, hospital, and daycare settings.
However, the discovery of a novel virus or bacterium may not necessarily be clinically relevant. Merely detecting a virus in clinical samples does not prove whether it is part of normal flora, a bystander, or a true pathogen. In cases where the pathogen, clinical syndrome, and epidemiology findings are linked, a strong case can be made for causality. For example, we recently used the Virochip to detect a novel human cardiovirus in children with acute respiratory and diarrheal illness ( Fig. 2A) . Subsequently, we cultured the cardiovirus in human cell lines (Fig.  2B ) and detected an acute seroconversion event in a child with diarrhea and vomiting in a household infected with cardiovirus ( Fig. 2C) , thus linking cardiovirus infection with diarrheal symptoms.
Even if a novel agent causes a disease, developing and validating diagnostic tests for that agent might not be justified if the disease is benign or if diagnosis has no impact on clinical management. Nevertheless, as in the 2009 H1N1 influenza pandemic, identifying novel pathogens can rapidly spur efforts to develop tests to monitor outbreaks as well as effective drugs and vaccines to treat the disease.
Validation, Quality Control, and Regulatory Issues
It is not feasible to verify acceptable test results for hundreds to thousands of individual targets in broad-spectrum microarrays. Instead, quality control relies on validating each step of the assay while verifying only the most common infectious agents. Thus, it becomes necessary to confirm unusual results with some other method, such as pathogen-specific PCR, serology, or sequencing, while the clinical significance of atypical or novel pathogens has to be carefully considered with clinicians ordering the tests and caring for particular patients.
Clinical laboratories validate tests before they are used for guiding patient care. Diagnostic tests typically adhere to FDA-approved protocols, use standardized reagents, and are approved based on their ability to diagnose disease. Clinical laboratories that are certified according to the Clinical Laboratory Improvement Amendments (CLIA) are permitted to perform in-lab validated or "homebrew" tests. Because such tests are not FDA-approved, CLIA-certified labs are required to show clinical utility of those tests and to standardize their performance characteristics. Typically, the FDA requires patient outcome data for each pathogen included in an infectious disease test panel. The weakness of this system was exposed during the 2009 H1N1 influenza pandemic. At the outset, no FDAapproved test was available to detect this specific strain of the influenza virus. Then diagnostic laboratories and test manufacturers played "catch-up" as the FDA began approving tests for the virus on an emergency use authorization (EUA) basis. Soon after the 2009 H1N1 outbreak began, the Virochip system identified the H1N1 virus as a novel strain that was most similar to a swine influenza strain (Fig. 3A) . While "homebrew" assays such as the Virochip may be useful for detecting emerging pathogens, their distribution is very limited because the test is not FDA-approved. One approach to expediting FDA review might be to validate targeted microarrays containing specific categories of pathogens such as biothreat agents or retroviruses or tailored to specific disease states, such as those causingrespiratory illnesses, diarrhea, sepsis, or encephalitis. We are actively exploring this strategy forgaining FDA approval for such microarray assays.
An additional complication arises from dependence on algorithms to interpret results from microarrays and deep sequencing analyses. In 2006, FDA officials issued a draft guidance, "In Vitro Diagnostic Multivariate Index Assays (IVD-MIA)," which recommends formal reviews for any diagnostic device that combines multiple variables to yield a single "index" or "score" that "cannot be independently derived or verified by the end user." In short, this guidance urges that algorithms be validated, a process that would significantly increase the time and resources needed to validate such systems and could further delay their commercial development as well as increase their cost to users.
Deep Sequencing Technology
Deep sequencing involves highly parallel DNA sequence analysis, yielding thousands to millions of sequence reads per run. Typically, each DNA sequence contains 36 -500 base pairs, with some technologies producing paired-end reads that contain information from both ends of a DNA molecule. The instruments now typi- cally used for identifying and analyzing pathogens include the Roche 454 pyrosequencing system and the Illumina Genetic Analyzer. While single runs can cost several thousand dollars, "barcode" adapters reduce costs by enabling simultaneous analyses of multiple samples. Costs are expected to continue to fall as these technologies continue to evolve.
While deep sequencing is not currently being used for diagnostic tests, it has been used to identify several novel viruses, including the hemorrhagic fever Lujo virus from South Africa; the Dandenong virus, an arenavirus associated with fatal diseases in transplant recipients; the Merkel cell polyomavirus, associated with a rare skin cancer; and several viruses associated with gastroenteritis such as cosavirus and klassevirus / salivirus. Deep sequencing was also applied to examine minority quasispecies of HIV-1 to detect rare resistance determinants and to test vaccines for low-level contaminants such as the porcine circoviruses that were found in the RotaTeq vaccine. Researchers are also using deep sequencing as a metagenomics approach to discern organism profiles in clinical samples. For example, the Human Microbiome Project relies on deep sequencing to follow changes in human flora associated with diseases affecting the mouth, skin, vagina, gut, and respiratory tract.
We recently applied deep sequencing technology to 17 respiratory samples collected from individuals infected with the 2009 H1N1 influenza virus early during the pandemic. Our analysis confirmed that the virus was the sole infectious agent common to all 17 cases. We also tested whether we could use a deep sequencing approach to identify novel viruses by attempting to de novo assemble the influenza genome after removing all influenza sequences from the reference database. Indeed, we were able to assemble the nearly complete sequence of all eight segments of the influenza genome without relying on a priori knowledge of the influenza (Orthomyoviridae) family (Fig. 3B) . Thus, a diagnostic strategy of rapid Virochip-based testing followed by deep sequencing could prove to be a useful public health response to infectious disease outbreaks in the future.
Challenges Interpreting Bioinformatics Data
Correctly interpreting the clinical significance of microarray and sequencing data remains a formidable challenge. For example, where samples are polymicrobial or agents are present at low levels, supportive clinical and epidemiological information might be required to draw clinically meaningful conclusions.
Another challenge is to determine which algorithms and what analytic methods will yield the most clinically meaningful results. When using the Virochip, we typically perform three different sets of analyses. Rank analysis by raw intensity data or Z-scores highlights the probes with high signal intensity, thus pinpointing the virus that is present. Hierarchical cluster analysis reveals a visual pattern of probe signals corresponding to a known virus or viral strain (Fig.  3A) . E-Predict and related algorithms compare the microarray hybridization pattern from a clinical sample to profiles from viruses in the GenBank sequence database (Fig. 4) .
Because deep sequencing provides no visual check of the raw data, we depend on sequence alignments to identify species. Some instruments yield longer DNA reads, which are useful for identifying novel and/or divergent pathogens and de novo genome assembly, while others have better depth of coverage (more sequences), which increases sensitivity as well as accuracy. Clinical samples can be difficult to analyze. For instance, we sometimes need to treat respiratory samples from influenza patients with DNase to remove host background DNA. Moreover, having two closely related species in the same sample can cause assembly errors, leading to false chimeric assemblies. Thus, deep sequencing analysis requires careful consideration of the sample type, processing method, and background flora.
